Accelerated radiotherapy equivalent to conventional for prostate cancer

Accelerated radiotherapy equivalent to conventional for prostate cancer

26 Sep 2016

Early stage, low-risk prostate cancer patients, can be treated with hypo-fractionated radiation therapy in one-third shorter treatment time than conventional radiotherapy. This treatment offers comparable outcomes and health-related quality of life.

While efficacy results from the trial "NRG Oncology/RTOG 0415" were reported previously, the first research was presented to report its patient-reported outcomes, which included patients from across the U.S. and Canada.

This trial assessed the differences in health-related quality of life (HRQOL), including bowel, urinary, sexual and hormonal side effects, following a conventional or fractionated RT schedule.

Conventional versus Hypo-fractionated radiotherapy

Compared to conventional (C)RT, hypo-fractionated (H)RT is delivered in larger doses over a shorter period of time.

“Studies have suggested that higher amounts of radiation over shorter periods of time might be more effective in destroying cancer cells, but the concern has been that stronger doses might also cause quality of life issues such as more diarrhea or decrease in sexual function,” said lead study author Deborah Watkins Bruner, PhD, a professor at the Nell Hodgson Woodruff School of Nursing and a professor of radiation oncology at Emory University School of Medicine in Atlanta.

Patients in the study were randomly assigned to receive either conventional RT, consisting of 73.8 Gy (=unit of absorbed radiation) in 41 daily treatments delivered over 8.2 weeks, or hypo-fractionated RT, consisting of 70 Gy in 28 daily treatments delivered over 5.6 weeks.

A total of 962 patients reported HRQOL data. The median patient age was 67 years, and baseline characteristics were similar between the treatment groups.


Health-related quality of life (HRQOL)

HRQOL was assessed with the Expanded Prostate Index Composite (EPIC), a comprehensive instrument designed to evaluate patient-reported side effects after prostate cancer treatment.

The questionnaire measured side effects in each of EPIC’s four domains – bowel, urinary, sexual and hormonal. EPIC assesses prostate cancer-specific HRQOL on a Likert scale with responses transformed to 0-100, where higher scores indicate a better HRQOL.

Participant feedback was collected at baseline, 6 months after treatment began and 1 year post-treatment, with change scores compared between the groups. A Wilcoxon test was used to assess differences.

At baseline, there were no statistically significant differences between treatment groups in any of the HRQOL domains.

Results indicated that, compared to men without prostate cancer, most patients reported poor baseline EPIC sexual domain scores. At baseline, the patients reported only slightly lower than average bowel and urinary scores.

Following treatment, patients who received higher doses of RT in fewer sessions reported similar HRQOL as the patients who received conventional RT.

The result

There were no differences in change scores for either group on any EPIC domain at 6-months follow-up. At 12-months follow-up, hypo-fractionation patients reported a larger decline in the bowel domain compared to those who received conventional RT, with an average from baseline of -3.6 vs. -1.8, respectively, but the change was not deemed clinically significant to patients.

“This research shows that hypo-fractionated radiation therapy offers patients value-based care for their disease. If patients with low-risk prostate cancer choose radiation therapy, they can live equally long and have the same quality of life outcomes with 28 daily treatments, compared to what has been the standard care of 41 daily treatments,” said Dr. Bruner.

This reduction of treatment time by almost a third translates into other types of value for patients, such as decreased drive time, lower transportation costs and fewer days off of work.”


Source: eCancer News

Login to your account

Did you forget your password?